Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2003-01-22
2004-06-15
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S638000, C514S773000, C514S611000, C514S934000, C514S788100, C514S183000
Reexamination Certificate
active
06750254
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, to compositions comprising such compounds, to methods of using such compounds and compositions, to a method for the preparation of nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates via the direct reaction of nitric oxide with amidines and enamines, and to a method of converting amine's into such compounds.
BACKGROUND OF THE INVENTION
Nitric oxide (NO) has been implicated as part of a cascade of interacting agents involved in a wide variety of bioregulatory processes, including the physiological control of blood pressure, macrophage-induced cytostasis and cytotoxicity, and neurotransmission (Moncada et al., “Nitric Oxide from L-Arginine: A Bioregulatory System,”
Excerpta Medica
, International Congress Series 897, Elsevier Science Publishers B. V.: Amsterdam (1990); Marletta et al.,
Biofactors
2: 219-225 (1990); Ignarro,
Hypertension
(
Dallas
) 16: 477-483 (1990); Kerwin et al.,
J. Med. Chem
. 38: 4343-4362 (1995); and Anggard,
Lancet
343: 1199-1206 (1994)). Given that NO plays a role in such a wide variety of bioregulatory processes, great effort has been expended to develop compounds capable of releasing NO. Some of these compounds are capable of releasing NO spontaneously, e.g., by hydrolysis in aqueous media, whereas others are capable of releasing NO upon being metabolized (Lefer et al.,
Drugs Future
19: 665-672 (1994)).
Keefer et al. (U.S. Pat. Nos. 4,954,526; 5,039,705; 5,155,137; 5,208,233 and 5,405,919 and related patents and patent applications, all of which are incorporated herein by reference) disclose, among others, the use of certain nucleophile
itric oxide adducts as NO-releasing agents, i.e.,
in which the nucleophilic residue (Nuc) is a primary amine, a secondary amine or a polyamine. Although such adducts offer many advantages over other currently available nitric oxide-releasing compounds, one disadvantage presented by the use of such adducts as pharmaceutical agents is the potential risk of release of nitrosamines, which are carcinogenic, upon decomposition and release of NO. Another disadvantage of the adducts of primary amines is that they can be unstable even as solids due to a tendency to form traces of potentially explosive diazotates.
Several types of compounds of the general structure
have been known for many years. Traube (
Liebigs Ann. Chem
. 300: 81-123 (1898)) reported the preparation of a number of such compounds and noted that treatment of the compounds with acid produced a “brown gas.” Although brown gas suggests the release of NO, given that a brown gas also may be produced in the disproportionation of nitrite, the release of brown gas by the compounds prepared by Traube is not, in and of itself, evidence of NO release. Compounds of the structural type reported by Traube are known to require harsh treatment with mineral acids to release any gas which is, of course, incompatible with a biological utility.
Another compound, which has the structure
and which has been named cupferron, has been shown by Kubrina et al.,
Izvestia Akademii Nauk SSSR Seriia Biologicheskaia
6: 844-850 (1988)) to generate NO in vivo. In addition, the antibiotics alanosine (C(O)(OH)CH(NH
2
)CH
2
N(O)═NOH) and dopastin (CH
3
CH═CHC(O)NHCH
2
CH(i-propyl)-N(O)═NOH), as well as cupferron, have been shown to release NO in vivo by enzymatic oxidation (Alston et al.,
J. Biol. Chem
. 260: 4069-4074 (1985)).
More recently, Keefer et al., in U.S. Pat. No. 5,212,204, have broadly described that an organic moiety may be linked via carbon to the N
2
O
2
−
group. This patent does not disclose an amidine or enamine structure as the nucleophile, nor does it teach the nature of the structural characteristics that an organic moiety must possess to cause the resulting N
2
O
2
−
group to be a nitric oxide donor.
Some N
2
O
2
−
-containing compounds have been disclosed to be useful as curing agents in rubber manufacture, antiknock additives for gasoline, indicator dyes, explosives, corrosion inhibitors and fungicides (Danzig et al., U.S. Pat. No. 3,309,373; Wiersdorff et al.,
Chem Abstracts
77: 48034f (1972); Massengale, U.S. Pat. No. 2,635,978; and Metzger et al., U.S. Pat. No. 2,954,314). However, the mechanism of the reported action of these compounds was not described.
In this regard, a recent study of the N
2
O
2
−
group (Taylor et al.,
J. Org. Chem
. 60: 435-444 (1995)) proposed a mechanism for the observed NO release. The proposed mechanism was based on quantum mechanical calculations which showed protonation at the terminal oxygen to be most favored thermodynamically in the case of N bound N
2
O
2
−
.
None of the above disclosures, however, mention anything about the release of nitroxyl (HNO, which, at the physiological pH of 7.4, exists as NO
−
) by this functional group. Recent results suggest that, under certain conditions, many classes of “NO donors” may release some NO
−
(see the discussions for nitrosothiols and diazeniumdiolates as well as the table of NO donors in Feelisch et al., Donors of Nitrogen Oxides,
In Methods in Nitric Oxide Research
, M. Feelisch and J. S. Stamler, Eds., Ch. 7, pp. 71-115, John Wiley and Sons, New York (1996)).
To date, there are three compounds used to generate HNO in solution. One compound, Angeli's salt, which is the standard HNO source (Fukuto et al.,
J. Pharm. Exp. Ther
. 263: 546-551 (1992)), is, of course, an inorganic salt. The other two compounds, acetylated Piloty's acid (Smith et al.,
J. Amer. Chem. Soc
. 82: 5731-5740 (1960)) and benzoylated hydroxycyanamide (Lee et al.,
J. Med. Chem
. 35 3648-3652 (1992)) are promising inhibitors of aldehyde dehydrogenase. However, even in these compounds, there is debate as to whether the observed physiological effects are attributed to NO, or to NO
−
. For example, Piloty's acid has been shown to release NO oxidatively under physiological conditions (Zamora et al.,
Biochem. J
. 312: 333-339 (1995)).
Reports that superoxide dismutase can prolong the effects of NO via its reversible reduction to NO
−
(Murphy et al.,
PNAS USA
88: 10860-10864 (1991)) and that NO
−
, itself, exhibits potent activity as a vasodilator (Fukuto et al.,
J. Pharm. Exp. Ther
. 263: 546-551 (1992)) and as an inhibitor of aldehyde dehydrogenase (Lee et al.,
J. Med. Chem
. 35: 3648-3652 (1992)) suggest that compounds, which release either NO or NO
−
or mixtures of the two, are potentially useful pharmaceutical agents and may even offer advantages over compounds that just release NO.
Despite the extensive literature available on NO and nitric oxide-releasing compounds, there remains a need for stable nitric oxide-releasing compounds in which the nitric oxide-releasing group N
2
O
2
−
is bonded directly to a carbon atom and which can be prepared from compounds that do not include a nitrogen atom suitable for conversion to a diazeniumdiolate.
Accordingly, it is an object of the present invention to provide a chemical structural framework having an atomic and electronic arrangement such that an N
2
O
2
−
functional group attached thereto will serve as a spontaneous NO and/or NO
−
donor. It is a further object of the present invention to provide a method for producing novel NO and/or NO
−
-releasing diazeniumdiolates in which the N
2
O
2
−
group is bound to a carbon atom. Another object of the present invention is to provide NO- and/or NO
−
-releasing derivatives of amidines and enamines. A related object of the present invention is to provide NO- and/or NO
−
-releasing derivatives of known pharmaceutical agents. A more specific object is to provide NO- and/or NO
−
-releasing derivatives of known pharmaceutical agents whose nitrogen atoms do not provide suitable N-diazeniumdiolates as nitric oxide donors. Yet another object of the present invention is to provide compositions comprising NO- and/or NO
−
-r
Hrabie Joseph A.
Keefer Larry K.
Patel Sudhaker B.
Raymond Richard L.
The United States of America as represented by the Department of
LandOfFree
Nitric oxide-releasing amidine—and enamine-derived... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nitric oxide-releasing amidine—and enamine-derived..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nitric oxide-releasing amidine—and enamine-derived... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3365770